Cannabidiol (CBD) Research

Cannabidiol (CBD) RESEARCH Suggested Cannabidiol (CBD) Dosage
The following is a general guideline based on patient response and manufacturers. A patient must find their own efficacy as each person will experience varying degrees of CBD needed to properly coat the Synaptic Clefs. Read More

Fatty Acid Modulation of the Endocannabinoid System and the Effect on Food Intake and Metabolism
Endocannabinoids and their G-protein coupled receptors (GPCR) are a current research focus in the area of obesity due to the system’s role in food intake and glucose and lipid metabolism… Read More

The endocannabinoid system in anxiety, fear memory and habituation

Evidence for the involvement of the endocannabinoid system (ECS) in anxiety and fear has been accumulated, providing leads for novel therapeutic approaches. In anxiety, a bidirectional influence of the ECS has been reported, whereby anxiolytic and anxiogenic responses have been obtained after both increases and decreases of the endocannabinoid tone.Read More

Twin Falls Biotech CBD – Company Studies: CBD Product Development
There are many published studies on buccal cavity administration of cannabinoids – almost all funded by GW Pharma for their drug approvals.  Buccal cavity identified as the mouth and linings of the esophagus. Twin Falls Biotech studied their millions of dollars of investment and research “in the best delivery of cannabinoids” by GW Pharma, as we entered the market space of CBD infused dietary supplements…..Read More

Whitepaper: Dosing Medical Marijuana: Rational Guidelines on Trial in Washington State
The medicinal value of cannabis is well documented in the medical literature.[1,2] Cannabinoids, the active ingredients, are found in the resin-producing pistillate inflorescences of the Cannabis sativa plant.[3] Since the early 1900s, cannabis has been referred to as mari(h/j)uana, a pejorative term derived from Mexican Spanish-Portuguese colloquial slang. Cannabinoids have many distinct pharmacologic properties….Read More

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
The therapeutic potential of cannabidiol (CBD), the major nonpsychoactive component of cannabis, was explored in murine collagen-induced arthritis (CIA). CIA was elicited by immunizing DBA/1 mice with type II collagen (CII) in complete Freund’s adjuvant…Read More

Cannabinoids and the Imune System: Potential for the treatment of inflammatory diseases?
Since the discovery of the cannabinoid receptors and their endogenous ligands, significant advances have been made in studying the physiological function of the endocannabinoid system….Read More